Bio-Techne Corporation has released a corporate presentation highlighting its focus on purposeful innovation to advance science and medicine. The company, a leader in proteomics for 48 years, outlines its differentiated portfolio that serves high-growth markets. The presentation details their segments and product portfolio, including Protein Sciences, Cell Therapy, Diagnostics, and Spatial Biology. Bio-Techne reported FY2024 revenues of approximately $1.2 billion, with a significant portion derived from consumables. The company operates globally with headquarters in Minneapolis, MN, employing around 3,100 people across 34 worldwide locations. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.